Regorafenib

Search with Google Search with Bing

Information
Drug Name
Regorafenib
Description
Entry(CIViC)
31
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
colorectal adenocarcinoma KDR p.Arg961Trp (p.R961W)
( ENST00000263923.5 ) KDR p.Arg961Trp (p.R961W)
( ENST00000263923.5 ) 		C Predictive Supports Sensitivity/Response Somatic 1 27004155 Detail
colorectal cancer KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		D Predictive Supports Resistance Somatic 2 26161928 Detail
colorectal cancer KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		D Predictive Supports Resistance Somatic 26161928 Detail
colorectal cancer KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		D Predictive Supports Resistance Somatic 26161928 Detail
colorectal cancer KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Resistance Somatic 26161928 Detail
colorectal cancer KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Resistance Somatic 26161928 Detail
colorectal cancer KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		D Predictive Supports Resistance Somatic 26161928 Detail
gastrointestinal stromal tumor KIT V560_L576DEL KIT V560_L576DEL D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT EXON 9 MUTATION KIT EXON 9 MUTATION C Predictive Supports Reduced Sensitivity Somatic 3 27371698 Detail
gastrointestinal stromal tumor BRAF MUTATION BRAF MUTATION C Predictive Does Not Support Sensitivity/Response Somatic 2 27371698 Detail
gastrointestinal stromal tumor KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT EXON 9 MUTATION KIT EXON 9 MUTATION B Predictive Supports Reduced Sensitivity Somatic 2 22614970 Detail
gastrointestinal stromal tumor KIT UNKNOWN KIT W557_V559insC B Predictive Supports Sensitivity/Response Somatic 2 27371698 Detail
gastrointestinal stromal tumor KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Resistance Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT P551_E554delPMYE KIT P551_E554delPMYE D Predictive Does Not Support Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Resistance Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Asp821Tyr (p.D821Y)
( ENST00000412167.7, ENST00000689832.1, ENST00000288135.6, ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp821Tyr (p.D821Y)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Sensitivity/Response Somatic 2 22614970 Detail
gastrointestinal stromal tumor KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000288135.6, ENST00000412167.7, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Sensitivity/Response Somatic 2 22614970 Detail
gastrointestinal stromal tumor KIT EXON 11 MUTATION KIT EXON 11 MUTATION B Predictive Supports Sensitivity/Response Somatic 2 23177515 Detail
gastrointestinal stromal tumor BRAF MUTATION BRAF MUTATION C Predictive Supports Resistance Somatic 1 22614970 Detail
gastrointestinal stromal tumor KIT EXON 9 MUTATION KIT EXON 9 MUTATION B Predictive Supports Sensitivity/Response Somatic 2 23177515 Detail
gastrointestinal stromal tumor KIT EXON 11 MUTATION KIT EXON 11 MUTATION B Predictive Supports Sensitivity/Response Somatic 2 22614970 Detail
gastrointestinal stromal tumor KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT EXON 11 MUTATION KIT EXON 11 MUTATION B Predictive Supports Sensitivity/Response Somatic 3 27371698 Detail
gastrointestinal stromal tumor KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
colorectal cancer PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		B Predictive Does Not Support N/A Somatic 4 24559322 Detail
colorectal cancer KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 4 24559322 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Case Report of a 84-year-old woman with stage IVb ... KDR KDR p.Arg961Trp (p.R961W)
( ENST00000263923.5 ) KDR p.Arg961Trp (p.R961W)
( ENST00000263923.5 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing ... KRAS KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing... KRAS KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing ... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing ... KRAS KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing ... KRAS KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) KRAS p.Gly12Arg (p.G12R)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, a SW48 cell line expressing ... KRAS KRAS p.Gly12Ser (p.G12S)
( ENST00000685328.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ser (p.G12S)
( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000686969.1, ENST00000556131.2, ENST00000557334.6, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
A GIST430 patient derived cell line expressing KIT... KIT KIT V560_L576DEL KIT V560_L576DEL Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
This phase II clinical trial of regorafenib (NCT01... KIT KIT EXON 9 MUTATION KIT EXON 9 MUTATION N/A true CIViC Evidence detail
This phase II clinical trial of regorafenib (NCT01... BRAF BRAF MUTATION BRAF MUTATION Sensitivity false CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
This retrospective study of a phase 2 clinical tri... KIT KIT EXON 9 MUTATION KIT EXON 9 MUTATION N/A true CIViC Evidence detail
This phase II clinical trial of regorafenib (NCT01... KIT KIT UNKNOWN KIT W557_V559insC Sensitivity true CIViC Evidence detail
A preclinical study tested the effects of tyrosine... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT P551_E554delPMYE KIT P551_E554delPMYE Sensitivity false CIViC Evidence detail
In an in vitro kinase study, a KIT V559D primary a... KIT KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
A preclinical study tested the effects of a tyrosi... KIT KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
This retrospective study of a phase 2 clinical tri... KIT KIT p.Asp821Tyr (p.D821Y)
( ENST00000412167.7, ENST00000689832.1, ENST00000288135.6, ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp821Tyr (p.D821Y)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
This retrospective study of a phase 2 clinical tri... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000288135.6, ENST00000412167.7, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
This international, placebo controlled prospective... KIT KIT EXON 11 MUTATION KIT EXON 11 MUTATION Sensitivity true CIViC Evidence detail
This retrospective study of a phase 2 clinical tri... BRAF BRAF MUTATION BRAF MUTATION Resitance or Non-Reponse true CIViC Evidence detail
This international, placebo controlled prospective... KIT KIT EXON 9 MUTATION KIT EXON 9 MUTATION Sensitivity true CIViC Evidence detail
This retrospective study of a phase 2 clinical tri... KIT KIT EXON 11 MUTATION KIT EXON 11 MUTATION Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity false CIViC Evidence detail
This phase II clinical trial of regorafenib (NCT01... KIT KIT EXON 11 MUTATION KIT EXON 11 MUTATION Sensitivity true CIViC Evidence detail
In an in vitro kinase study, a KIT V560G primary a... KIT KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Gly (p.V561G)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
PIK3CA mutation status was not predictive of respo... PIK3CA PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		N/A false CIViC Evidence detail
KRAS mutation status was not predictive of respons... KRAS KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION Sensitivity false CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04170556 Active, not recruiting Phase 1/Phase 2 Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) March 16, 2020 August 2024
NCT02098538 Active, not recruiting Phase 2 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma March 2014 March 2025
NCT04117945 Active, not recruiting Phase 2 Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer March 3, 2020 March 31, 2025
NCT04051606 Active, not recruiting Phase 2 Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma July 31, 2019 October 27, 2024
NCT05064059 Active, not recruiting Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) November 10, 2021 November 11, 2025
NCT04879368 Active, not recruiting Phase 3 RegoNivo vs Standard of Care Chemotherapy in AGOC June 1, 2021 June 1, 2026
NCT05600309 Active, not recruiting Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study June 14, 2022 July 31, 2025
NCT03994601 Active, not recruiting Phase 1/Phase 2 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers September 6, 2019 May 14, 2025
NCT03992456 Active, not recruiting Phase 2 Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer April 24, 2020 October 7, 2024
NCT04776148 Active, not recruiting Phase 3 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) March 29, 2021 September 27, 2024
NCT03844620 Active, not recruiting Phase 2 Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer January 29, 2019 August 31, 2024
NCT04757363 Active, not recruiting Phase 2 A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer February 11, 2021 February 2025
NCT02619435 Active, not recruiting Phase 2 Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer November 2015 November 2024
NCT04718909 Active, not recruiting Phase 2 Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC January 9, 2021 December 31, 2023
NCT02023333 Active, not recruiting Phase 2 Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma December 2013 December 2024
NCT02657551 Active, not recruiting Phase 2 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer January 2016 December 2024
NCT03793361 Active, not recruiting Phase 2 Phase II Study of Regorafenib as Maintenance Therapy May 15, 2019 March 2025
NCT03657641 Active, not recruiting Phase 1/Phase 2 Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer June 21, 2019 June 21, 2025
NCT05328908 Active, not recruiting Phase 3 A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer April 28, 2022 May 31, 2028
NCT05394740 Active, not recruiting Phase 1/Phase 2 Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy June 6, 2022 November 2025
NCT03563157 Active, not recruiting Phase 1/Phase 2 QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine May 25, 2018 December 30, 2022
NCT02365441 Active, not recruiting Phase 2 A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) June 30, 2015 December 31, 2023
NCT05198934 Active, not recruiting Phase 3 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation April 19, 2022 March 12, 2025
NCT04660812 Active, not recruiting Phase 1/Phase 2 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. May 10, 2021 July 2024
NCT05134532 Active, not recruiting Phase 2 Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC December 24, 2021 October 30, 2024
NCT03377361 Active, not recruiting Phase 1/Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread February 1, 2018 March 11, 2024
NCT02955940 Active, not recruiting Phase 2 An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib November 30, 2016 December 31, 2024
NCT04362839 Active, not recruiting Phase 1 Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer May 27, 2020 June 30, 2024
NCT02934529 Active, not recruiting Phase 3 Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab March 2015 December 2024
NCT02606097 Completed Phase 2 Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation April 2014 May 2018
NCT02638766 Completed Phase 2 Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST November 2015 August 31, 2021
NCT02651415 Completed Phase 2 Phase II Study of Perindopril and Regorafenib in mCRC August 2016 November 7, 2018
NCT02699073 Completed Phase 2 Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib February 2016 July 9, 2018
NCT02736305 Completed Phase 2 Use of Regorafenib in Recurrent Epithelial Ovarian Cancer February 3, 2016 November 18, 2019
NCT02788279 Completed Phase 3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) July 5, 2016 December 26, 2018
NCT02795156 Completed Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations September 28, 2016 August 17, 2022
NCT02835924 Completed Phase 2 Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC July 2016 September 2019
NCT02889328 Completed Phase 2 Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs September 2016 January 2018
NCT02926222 Completed Phase 2 Regorafenib in Relapsed Glioblastoma November 2015 June 2021
NCT01068769 Completed Phase 2 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor February 2010 August 2020
NCT01875380 Completed Phase 2 Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer June 2013 April 2016
NCT01896856 Completed Phase 1/Phase 2 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer October 23, 2013 August 26, 2019
NCT01900743 Completed Phase 2 Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma June 5, 2013 September 16, 2020
NCT01913639 Completed Phase 2 FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer July 2013 June 2019
NCT01929616 Completed Phase 2 Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) August 2013 June 17, 2019
NCT01996969 Completed N/A Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer October 2013 May 2016
NCT02024607 Completed Phase 1/Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer January 2014 November 2019
NCT02048371 Completed Phase 2 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes July 2014 May 2022
NCT02048722 Completed Phase 2 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma June 13, 2014 October 12, 2021
NCT02053376 Completed Phase 2 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy January 2014 May 14, 2018
NCT02080260 Completed Phase 2 A Study of Regorafenib in Advanced Pancreatic Cancer Patients June 6, 2014 June 28, 2017
NCT02095054 Completed Phase 1 Regorafenib and Cetuximab in Patients With Advanced Malignancy March 19, 2014 March 27, 2020
NCT02096354 Completed Phase 2 A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer May 2014 April 13, 2018
NCT02115542 Completed Phase 2 Single Agent Regorafenib in Refractory Advanced Biliary Cancers June 5, 2014 September 20, 2021
NCT02116894 Completed Phase 1 Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer August 2014 May 2016
NCT02164240 Completed Phase 1 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST July 2014 May 2021
NCT02195011 Completed Phase 2 Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases July 2014 June 4, 2017
NCT02259725 Completed Phase 2 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors August 16, 2016 August 20, 2020
NCT02307500 Completed Phase 2 Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy December 2014 August 2020
NCT02310477 Completed Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting February 2014 December 2014
NCT02316340 Completed Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer February 11, 2015 April 16, 2018
NCT02368886 Completed Phase 2 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer March 27, 2015 March 2, 2023
NCT02386397 Completed Phase 1/Phase 2 Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer September 2014 December 2019
NCT02406170 Completed Phase 1/Phase 2 Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma April 2015 October 2019
NCT02459119 Completed Phase 2 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) May 2015 April 2020
NCT02466009 Completed Phase 2 Regorafenib in Metastatic Colorectal Cancer March 2015 March 9, 2022
NCT02466802 Completed Phase 1 Study of Regorafenib and Sildenafil for Advanced Solid Tumors July 1, 2015 January 28, 2019
NCT02584465 Completed Phase 2 REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression August 28, 2015 September 19, 2021
NCT03010722 Completed Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy January 2015 July 2017
NCT03042689 Completed Phase 1 Study of Regorafenib in Patients With Advanced Myeloid Malignancies April 17, 2017 February 27, 2023
NCT03081494 Completed Phase 1 Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer June 9, 2017 May 7, 2019
NCT03215264 Completed Phase 1 To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer October 2, 2017 June 1, 2020
NCT03305913 Completed Phase 1 Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy July 31, 2017 April 26, 2019
NCT03406871 Completed Phase 1/Phase 2 Regorafenib and Nivolumab Simultaneous Combination Therapy January 25, 2018 November 26, 2020
NCT03465722 Completed Phase 3 (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST March 26, 2018 September 15, 2021
NCT03475251 Completed Phase 1 A Study of CS1003 in Subjects With Advanced Solid Tumors May 9, 2018 May 31, 2021
NCT03520842 Completed Phase 2 Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer August 14, 2018 June 15, 2022
NCT03698253 Completed N/A Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI October 1, 2013 June 1, 2018
NCT03712943 Completed Phase 1 Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer October 23, 2018 January 18, 2024
NCT03829852 Completed Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients February 11, 2019 December 8, 2020
NCT03898102 Completed Phase 2 Zinc Supplement in Regorafenib Treated mCRC Patient March 2016 March 2019
NCT04200404 Completed Phase 1/Phase 2 A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors December 13, 2019 August 18, 2021
NCT04534218 Completed Phase 2 Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer October 16, 2020 December 13, 2023
NCT06283134 Not yet recruiting Phase 1 A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer April 2, 2024 December 1, 2027
NCT05426811 Not yet recruiting Phase 1/Phase 2 Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients July 1, 2022 December 30, 2025
NCT05233358 Not yet recruiting N/A HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure February 1, 2022 February 1, 2025
NCT06455254 Not yet recruiting Phase 2 Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM June 2024 June 2026
NCT06454409 Not yet recruiting Phase 1 Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia March 20, 2025 February 17, 2027
NCT06283303 Not yet recruiting Phase 1 A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer April 2, 2024 November 30, 2025
NCT06006923 Not yet recruiting Phase 2 Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer May 2024 April 2029
NCT05993702 Not yet recruiting TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer September 1, 2023 June 1, 2025
NCT05524155 Not yet recruiting Phase 2 Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis September 2022 December 2024
NCT06425133 Not yet recruiting Phase 2 Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers September 2024 September 2028
NCT06087263 Not yet recruiting Phase 2 Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. April 30, 2024 July 1, 2034
NCT05794971 Recruiting Phase 3 Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases June 10, 2023 March 31, 2028
NCT06200363 Recruiting Phase 1 A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer September 21, 2023 November 2024
NCT03829462 Recruiting Phase 3 Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients March 28, 2019 September 2025
NCT03899428 Recruiting Phase 2 Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC May 2, 2019 December 31, 2025
NCT03970447 Recruiting Phase 2/Phase 3 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma July 30, 2019 June 2028
NCT04116541 Recruiting Phase 2 A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. January 28, 2020 November 2026
NCT04625907 Recruiting Phase 1/Phase 2 FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma September 17, 2020 June 2030
NCT04781192 Recruiting Phase 1/Phase 2 The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers March 22, 2022 December 2025
NCT04787341 Recruiting Phase 2 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence December 15, 2020 June 15, 2025
NCT04874207 Recruiting Phase 4 Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib October 22, 2021 May 2025
NCT05048017 Recruiting Phase 2 Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma October 1, 2021 December 1, 2025
NCT05057052 Recruiting Phase 2 Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis September 26, 2021 September 25, 2024
NCT05113368 Recruiting Phase 2 Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer June 28, 2022 December 1, 2024
NCT05159245 Recruiting Phase 2 The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs December 10, 2021 November 25, 2026
NCT05194293 Recruiting Phase 2 Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer July 1, 2023 December 5, 2028
NCT05366816 Recruiting Phase 2 ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST October 17, 2023 December 2028
NCT05395741 Recruiting Phase 1/Phase 2 Regorafenib in Patients With Refractory Primary Bone Tumors April 28, 2022 December 31, 2025
NCT05425940 Recruiting Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer September 7, 2022 February 2026
NCT05462613 Recruiting Phase 2/Phase 3 Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer May 9, 2023 November 2030
NCT05644379 Recruiting Phase 1 A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma November 25, 2022 November 2025
NCT05644392 Recruiting Phase 1 A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours November 25, 2022 November 25, 2025
NCT05672316 Recruiting Phase 1/Phase 2 Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy May 11, 2023 November 9, 2024
NCT05713994 Recruiting Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma May 19, 2020 December 30, 2024
NCT05717738 Recruiting Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma January 20, 2022 December 31, 2024
NCT05770882 Recruiting Phase 1/Phase 2 Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) April 25, 2023 January 31, 2026
NCT02693535 Recruiting Phase 2 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer March 14, 2016 December 31, 2025
NCT05811481 Recruiting Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy December 27, 2022 December 27, 2025
NCT05818267 Recruiting N/A Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC) June 26, 2023 November 2025
NCT05877001 Recruiting Phase 2 The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases May 30, 2023 March 1, 2025
NCT05962450 Recruiting Phase 2 Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy October 26, 2023 August 1, 2025
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT05963490 Recruiting Phase 2 Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer April 25, 2023 April 25, 2026
NCT05970705 Recruiting Phase 2 Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC July 1, 2023 July 4, 2026
NCT05985109 Recruiting Phase 2 KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer October 26, 2023 December 31, 2026
NCT06047379 Recruiting Phase 1/Phase 2 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis November 1, 2023 August 31, 2026
NCT06095375 Recruiting Phase 1 Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients July 4, 2022 December 2025
NCT06099821 Recruiting Phase 2 KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade October 25, 2023 December 31, 2026
NCT03627728 Recruiting Phase 2 Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer June 13, 2018 December 31, 2022
NCT02389244 Recruiting Phase 2 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas September 2014 March 2026
NCT04327700 Suspended Phase 2 Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib January 26, 2021 November 2025
NCT02402036 Terminated Phase 2 A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer February 2015 November 2017
NCT02425683 Terminated Phase 2 Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX March 26, 2015 September 21, 2017
NCT02664077 Terminated Phase 3 A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer June 2016 October 2019
NCT02383433 Terminated Phase 2 Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer June 14, 2016 May 10, 2018
NCT02278783 Terminated Phase 2 Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer March 2015 January 2017
NCT02581059 Terminated Phase 2 Efficacy of Ginseng for Patients on Regorafenib April 2016 June 22, 2018
NCT03555149 Terminated Phase 1/Phase 2 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) September 27, 2018 September 26, 2022
NCT02241720 Terminated Phase 2 Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers May 2014 September 2016
NCT04985136 Terminated Phase 3 A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) September 26, 2021 December 29, 2021
NCT03099486 Terminated Phase 2 Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC October 6, 2017 June 2, 2020
NCT02234180 Terminated Phase 2 Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery September 2014 June 8, 2016
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT02175654 Terminated Phase 2 Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab June 2014 February 2016
NCT02587650 Terminated Phase 2 Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma March 26, 2015 July 12, 2018
NCT02119676 Terminated Phase 2 Study of Ruxolitinib in Colorectal Cancer Patients March 2014 December 2016
NCT02910843 Terminated Phase 1 Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer February 22, 2017 December 31, 2021
NCT05130021 Unknown status Phase 2 A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer January 31, 2022 October 31, 2023
NCT02175095 Unknown status N/A [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib July 2014 April 2020
NCT03880877 Unknown status Phase 2 Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer February 26, 2019 December 31, 2021
NCT02501551 Unknown status Phase 2 Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy February 2015 June 2022
NCT02773524 Unknown status Phase 3 A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer November 2016 December 2022
NCT04431791 Unknown status Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer May 25, 2020 February 1, 2022
NCT04008511 Unknown status Phase 1/Phase 2 Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer July 2019 March 2024
NCT05025592 Unknown status cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC September 10, 2021 December 31, 2022
NCT01189903 Unknown status Phase 2/Phase 3 Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients January 2011
NCT02288078 Unknown status Phase 2 Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402) October 2014 September 2016
NCT04771715 Unknown status Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer May 1, 2019 March 31, 2021
NCT01949194 Unknown status Phase 2 Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers September 2013 December 2018
NCT02439723 Withdrawn Phase 1 Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients March 2016 December 2017
NCT02287727 Withdrawn Phase 2 Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment March 2015
NCT05900648 Withdrawn Phase 2 Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) May 17, 2023 February 9, 2024